CellCept, Mycophenolate
CellCept, Mycophenolate Newswire

CellCept, Mycophenolate Newswire

Comprehensive Real-Time News Feed for CellCept, Mycophenolate (generic).

Results 1 - 20 of 30 in CellCept, Mycophenolate (generic)

  1. Global Report on Organ Transplant Immunosuppressant Drugs MarketRead the original story w/Photo

    Friday Oct 9 | SBWire

    This report on the organ transplant immunosuppressant drugs market studies the current and future prospects of the global market. Organ transplant immunosuppressant drugs market are prescribed to patients during or after transplant of organs such as kidney, liver, heart, lung and bone marrow.


  2. Corbus Announces First Patient Dosed In Phase 2 Study Of Resunab For Systemic SclerosisRead the original story

    Tuesday Oct 6 | BioSpace

    Corbus Pharmaceuticals Holdings, Inc. , a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases, announced today that the first subject was dosed in the Phase 2 clinical study of its investigational new drug Resunab for the treatment of diffuse cutaneous systemic sclerosis . Resunab was granted Orphan Drug Designation and Fast Track status for the treatment of systemic sclerosis from the U.S. Food and Drug Administration earlier this year.


  3. Corbus Pharmaceuticals Announces First Patient Dosed in Phase 2 Study ...Read the original story w/Photo

    Wednesday Oct 7 | Market Wire

    Resunab was granted Orphan Drug Designation and Fast Track status for the treatment of systemic sclerosis from the U.S. Food and Drug Administration earlier this year. Principal investigator Robert Spiera, M.D., Director of the Vasculitis and Scleroderma Program at the Hospital for Special Surgery, Weill Cornell Medical College in New York City, commented, "Our patients recognize the unmet need for better therapies for systemic sclerosis, and are very receptive to participating in this careful early phase clinical trial aimed at evaluating the safety and potential efficacy of Resunab in treating this often devastating disease."


  4. Haploidentical T-cell replete transplantation with post-transplant...Read the original story

    Sep 12, 2015 | CiteULike

    Haploidentical T-cell replete transplantation with post-transplant cyclophosphamide for patients in or above the 6 decade of age compared with allogeneic hematopoietic stem cell transplantation from an HLA-matched related or unrelated donor. It has recently been shown that a T-replete allogeneic-hematopoietic stem-cell transplantation from a haploidentical donor could be a valid treatment for hematological malignancies.


  5. Renal injury induced in alloxan diabetic rats. Role of Mycophenolate Mofetil as therapeutic agent.Read the original story

    Sep 8, 2015 | CiteULike

    Renal injury may develop in uncontrolled chronic hyperglycemia due to increased oxidative stress and release of pro-inflammatory mediators, leading to diabetic complications. Mycophenolate Mofetil is an immunosuppressant drug, an inhibitor of inosine monophosphate dehydrogenase , relevant to inflammation processes.


  6. Purinergic receptors in tubulointerstitial inflammatory cells: a...Read the original story

    Aug 26, 2015 | CiteULike

    Recent studies have suggested that both the tubulointerstitial inflammatory cells and the activation of purinergic receptors integrate common mechanisms that result in salt-sensitive hypertension. The basis of this hypothesis is that renal endothelial cells release ATP in response to shear stress in the setting of hypertension.


  7. Interventions for preventing and treating kidney disease in Henoch-Schonlein Purpura (HSP).Read the original story

    Aug 25, 2015 | CiteULike

    Henoch-Schonlein purpura is the most common vasculitis of childhood but may occur in adults. This small vessel vasculitis is characterised by palpable purpura, abdominal pain, arthritis or arthralgia and kidney involvement.


  8. Efficacy and safety of mycophenolate mofetil treatment in IgA nephropathy: a systematic review.Read the original story

    Aug 25, 2015 | CiteULike

    To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document. IgA nephropathy is the most common primary glomerular disease worldwide and also the most frequent cause of kidney failure.


  9. Safety considerations when prescribing immunosuppression medication to pregnant women.Read the original story

    Aug 25, 2015 | CiteULike

    In the past two decades, the number of women with autoimmune and inflammatory diseases experiencing a pregnancy has significantly increased in parallel with the enormous advances in the diagnosis and management of these disorders. However, information regarding the safety of immunosuppressive agents comes from case reports and case series and no controlled trials are available.


  10. Immunosuppressive agents for treating IgA nephropathy.Read the original story

    Aug 19, 2015 | CiteULike

    IgA nephropathy is the most common glomerulonephritis world-wide and a cause of end-stage kidney disease in 15% to 20% of patients within 10 years and in 30% to 40% of patients within 20 years from the onset of disease. This is an update of a review first published in 2003.


  11. Targeting T helper 17 by mycophenolate mofetil attenuates diabetic nephropathy progression.Read the original story

    Aug 11, 2015 | CiteULike

    Proinflammatory T helper 1 and T helper 17 cell subsets have been reported to have an immunopathogenic role in metabolic disease. We previously demonstrated that CD4 T cells are increased in kidneys in type 2 diabetic patients.


  12. Steroid-refractory chronic GVHD trial results 'overestimate' treatment efficacyRead the original story w/Photo

    Jul 24, 2015 | Medical News

    Trial results for patients with steroid-refractory chronic graft versus host have overestimated the efficacies of treatments, suggests a meta-analysis published in The Lancet Haematology . However, the authors believe that future trials could reduce this bias by following a 61-point checklist of guidelines, based on the US National Institute of Health consensus project on SR-cGVHD in 2006.


  13. AAV1.NT-3 gene therapy attenuates spontaneous autoimmune peripheral polyneuropathyRead the original story

    Jul 23, 2015 | Gene Therapy

    Correspondence: Dr Z Sahenk, Center for Gene Therapy, The Research Institute at Nationwide Children’s Hospital, 700 Children’s Drive, Room WA3011, Columbus, OH 43205, USA. E-mail: [email protected] Received 5 March 2015; Revised 20 May 2015; Accepted 4 June 2015 Accepted article preview online 30 June 2015; Advance online publication 23 July 2015 The spontaneous autoimmune peripheral polyneuropathy model in B7-2 knockout non-obese diabetic mice shares clinical and histological features with chronic inflammatory demyelinating polyradiculoneuropathy .


  14. Efficacy of galactose and adalimumab in patients with resistant...Read the original story

    Jul 22, 2015 | BioMed Central

    This is an Open Access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver applies to the data made available in this article, unless otherwise stated.


  15. Acute Orthotopic Heart Transplantation Rejection With ST-Segment...Read the original story

    Jul 21, 2015 | Circulation

    From the Division of Cardiology , Department of Medicine , Montefiore Medical Center, Bronx, NY. Correspondence to Peter Vlismas, MD, Montefiore Medical Center, 111 E 210 St, N W 3 Room 351, Bronx, NY 10467.


  16. Preclinical report on allogeneic uterus transplantation in non-human primates.Read the original story

    Jul 13, 2015 | CiteULike

    Is it possible to perform allogeneic uterus transplantation with a donation from a live donor in a non-human primate species and what immunosuppression is needed to prevent rejection? Allogeneic UTx in the baboon is a donor- and recipient-safe surgical procedure; immunosuppression with induction therapy and a triple protocol should be used. UTx may become a treatment for absolute uterine factor infertility.


  17. Recent advances in autoimmune pancreatitisRead the original story

    Jun 28, 2015 | GastroHep.com

    Autoimmune pancreatitis is a form of chronic pancreatitis that is characterized clinically by frequent presentation with obstructive jaundice, histologically by a dense lymphoplasmacytic infiltrate with fibrosis, and therapeutically by a dramatic response to corticosteroid therapy. Dr Suresh Chan and colleagues from Minnesota, USA investigate the 2 disease types as well as recent advances in autoimmune pancreatiisis.


  18. mycophenolate mofetilRead the original story w/Photo

    Jun 2, 2015 | MedicineNet

    Jay W. Marks, MD, is a board-certified internist and gastroenterologist. He graduated from Yale University School of Medicine and trained in internal medicine and gastroenterology at UCLA/Cedars-Sinai Medical Center in Los Angeles.


  19. Donald Hricik, MD, Receives AST Lifetime Achievement AwardRead the original story

    May 18, 2015 | PRWeb

    The American Society of Transplantation awarded its highest honor, the Lifetime Achievement Award, to Donald Hricik, MD, at the recent American Transplant Congress. Dr. Hricik has moved the field forward through both his involvement in clinical trials that have shaped our care of transplant patients and through his education of the next generation of transplant professionals.


  20. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of ...Read the original story

    Apr 22, 2015 | CiteULike

    Non-nephrotoxic immunosuppressive strategies that allow reduction of calcineurin-inhibitor exposure without compromising safety or efficacy remain a goal in kidney transplantation. Immunosuppression based on the mammalian-target-of-rapamycin inhibitor everolimus was assessed as a strategy for elimination of calcineurin-inhibitor exposure and optimisation of renal-graft function while maintaining efficacy.